Compound Reference Overview
| Field | Value |
|---|---|
| Name | KPV (Lys-Pro-Val) |
| Reference Code | KPV |
| Category | Healing & Recovery Peptide |
| Example Strength | 10 mg vial (varies by formulation) |
| Reference Range | 200–500 mcg daily (investigational use) |
| Frequency | Once daily |
| Key Safety Warning | Anti-inflammatory fragment of α-MSH. Not FDA-approved for systemic injectable use. Use caution in pregnancy/breastfeeding and in patients on immunosuppressive therapy. |
Mechanism of Action (Educational)
KPV is a tripeptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains anti-inflammatory signaling properties without melanogenic (tanning) effects.
Preclinical data suggest KPV may reduce pro-inflammatory cytokine production, modulate NF-κB signaling, and support mucosal immune balance.
Most literature involves topical, gastrointestinal, or experimental inflammatory models. Systemic injectable use remains investigational.
Indications (Investigational / Literature)
- Inflammatory bowel disease research
- Skin inflammation models
- Systemic inflammatory signaling research
Administration (Investigational)
| Parameter | Details |
|---|---|
| Route | Subcutaneous |
| Frequency | Once daily |
| Injection Site | Abdomen |
| Timing | Any time of day |
Pharmacokinetics (Limited Human Data)
Comprehensive human pharmacokinetic data are limited. Biologic activity is typically described within hours, with anti-inflammatory effects reported over 1–2 weeks in investigational contexts.
Titration Schedule (Investigational)
No formal titration schedule is typically required. Reference dosing ranges from 200–500 mcg daily. Dose selection may be individualized based on tolerability and clinical framework.
Reconstitution & Concentration
(Mathematical Standardization Model)
For educational standardization purposes, a 10 mg vial reconstituted with 2 mL diluent yields:
5 mg/mL (5000 mcg/mL).
| Parameter | Value |
|---|---|
| Diluent | Bacteriostatic water (example only) |
| Example Reconstitution | 10 mg + 2 mL diluent |
| Resulting Concentration | 5 mg/mL (5000 mcg/mL) |
| Stability | Up to 28 days refrigerated (2–8°C; varies by formulation) |
Conversion Reference
- 0.04 mL (4 units) = 200 mcg
- 0.08 mL (8 units) = 400 mcg
- 0.10 mL (10 units) = 500 mcg
This section is provided strictly for arithmetic illustration and does not constitute dosing guidance.
Safety & Contraindications (Summary)
Contraindications
- Pregnancy or breastfeeding
- Known hypersensitivity
Drug Interactions
- Immunosuppressants (mild): Potential additive immunomodulatory effects
Adverse Events
- Injection site reactions
- Mild gastrointestinal upset
Serious Adverse Events
- Rare in limited investigational reports
Monitoring (Investigational)
- Inflammatory markers (if applicable)
- GI symptom tracking
- Skin condition changes
- General tolerance
Mathematical Calculation Tool
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
Disclaimer
KPV is not FDA-approved for systemic injectable use. This content is provided strictly as a pharmacologic and mathematical reference for educational and professional purposes. It does not constitute medical advice or prescribing guidance. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.
Reference Sources
1. Getting SJ, et al. The anti-inflammatory effects of alpha-MSH-derived peptides.
J Leukoc Biol. 2001; PMID: 11509737.
2. Manna SK, et al. Alpha-MSH inhibits NF-κB activation and inflammatory signaling.
J Immunol. 2006; PMID: 17185996.
3. Brzoska T, et al. Alpha-MSH and immune regulation.
Endocr Rev. 2008; PMID: 19592591.